Europe In-Silico Trials: Computational Modelling and Simulation for Medical Product Innovation and Regulatory Clearance Market Growth by 2028

The Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is expected to reach US$ 1,870.3 million by 2028 from US$ 816.0 million in 2021; it is estimated to grow at a CAGR of 12.6% from 2021 to 2028.

In-silico clinical trials can supplement phase II drug trials to explore the safety and efficacy in the more infrequent phenotypes that usually appear only in phase III and predict the dose-effect relationship. Computational study in natural drug discovery is used to determine the metabolic pathways of active molecules and find the new targets and new molecules with high affinity to those targets. For instance, camptothecin derivatives (monoterpene-indole alkaloids) have been clinically employed as antitumor drugs. Such studies may explain how an in-silico metabolic analysis can improve the experimental decorations to gain more comprehensible biological information. Another aspect of human trials is that they are expensive, lengthy, and are typically designed with a narrow scope. But in-silico trials can be designed to answer a wide variety of relevant questions by providing sufficient statistical power to test the different hypotheses with a relatively small increase in resources associated with evaluating more models once the computational machinery is developed and implemented.

Furthermore, unlike conventional clinical trials, in-silico clinical trials are readily approved and authorized by the food and drug administration (FDA). Incrementally but inevitably, the in-silico clinical trial approach is expected to become the most significant evidence for regulatory evaluations. These factors indicate that the benefits mentioned above are substantially driving the in-silico trial market in Europe.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market at a promising CAGR during the forecast period.

Europe In-Silico Trials: Computational Modelling and Simulation for Medical Product Innovation and Regulatory Clearance Market Revenue and Forecast to 2028 (US$ Million)

The market for in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into organization size, offerings, application, clinical indication, and end user. Based on organization size, the Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into small and medium organizations and large organizations. Based on offerings, the Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into products, platforms, and services. Based on application, the Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into product design and discovery, product development, pre-clinical targeting, assessment of drugs and other biomedical products, and others. Based on clinical indication, the Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into cardiovascular diseases, neurodegenerative diseases, oncology, rare diseases, metabolic diseases, immune based diseases, infectious diseases, and others. Based on end user, the in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into pharmaceutical and biopharmaceutical companies, medical technology companies, contract research organizations, and others. By country, the Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented into Germany, the UK, France, Spain, Italy, and the rest of Europe.

InSilicoTrials Technologies; Feops; CADFEM Medical GmbH; Dassault Systèmes SE; Virtonomy GmbH; Certara Inc.; Computational Life; NOVA; TwInsight Medical; Ansys, Inc.; Synopsys, Inc.; Sensyne Health plc.; and Cerner Corporation are among the leading companies in the Europe in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market.                

Europe In-Silico Trials: Computational Modelling and Simulation for Medical Product Innovation and Regulatory Clearance Report Scope